Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

NCT01998984 ·Status: COMPLETED ·Phase: PHASE2

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

NCT01600014 ·Status: COMPLETED ·Phase: PHASE3

Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin

NCT03508856 ·Status: COMPLETED ·Phase: NA

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

NCT02361216 ·Status: COMPLETED ·Phase: PHASE3

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

NCT01803477 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

NCT01820260 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

NCT02251652 ·Status: COMPLETED ·Phase: PHASE4

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

NCT01541553 ·Status: COMPLETED ·Phase: PHASE3

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367 ·Status: COMPLETED ·Phase: PHASE1

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

NCT01449513 ·Status: COMPLETED ·Phase: PHASE1

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912 ·Status: COMPLETED ·Phase: PHASE3

Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis

NCT02716714 ·Status: COMPLETED ·Phase: PHASE4

PMS to Evaluate the Safety and Efficacy of Picato® Gel

NCT02421471 ·Status: COMPLETED

The Real Life Topical Field Treatment of Actinic Keratosis Study

NCT02362152 ·Status: COMPLETED

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

NCT02446223 ·Status: COMPLETED ·Phase: PHASE4

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

NCT01703078 ·Status: COMPLETED ·Phase: PHASE1

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

NCT02654769 ·Status: COMPLETED ·Phase: PHASE3

To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis

NCT02459795 ·Status: COMPLETED ·Phase: PHASE3

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

NCT00942604 ·Status: COMPLETED ·Phase: PHASE3

To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

NCT02385318 ·Status: COMPLETED ·Phase: PHASE3

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

NCT02124239 ·Status: COMPLETED ·Phase: PHASE1

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

NCT01926496 ·Status: COMPLETED ·Phase: PHASE4

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

NCT01387711 ·Status: COMPLETED ·Phase: PHASE1

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

NCT01787383 ·Status: COMPLETED ·Phase: PHASE3

Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis

NCT02242747 ·Status: COMPLETED ·Phase: NA